Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

HSP70IQ435A-Encoding DNA Repigments Vitiligo Lesions in Sinclair Swine.

Henning SW, Fernandez MF, Mahon J, Duff R, Azarafrooz F, Guevara-Patiño JA, Rademaker AW, Salzman A, Le Poole IC.

J Invest Dermatol. 2018 Jul 18. pii: S0022-202X(18)32334-0. doi: 10.1016/j.jid.2018.06.186. [Epub ahead of print]

PMID:
30031029
2.

Molecular properties of gp100-reactive T cell receptors drive the cytokine profile and antitumor efficacy of transgenic host T cells.

Eby JM, Smith AR, Riley TP, Cosgrove C, Ankney CM, Henning SW, Paulos CM, Garrett-Mayer E, Luiten RM, Nishimura MI, Baker BM, Le Poole IC.

Pigment Cell Melanoma Res. 2018 Jul 15. doi: 10.1111/pcmr.12724. [Epub ahead of print]

PMID:
30009548
3.

Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma.

Klarquist J, Tobin K, Farhangi Oskuei P, Henning SW, Fernandez MF, Dellacecca ER, Navarro FC, Eby JM, Chatterjee S, Mehrotra S, Clark JI, Le Poole IC.

Cancer Res. 2016 Nov 1;76(21):6230-6240. Epub 2016 Sep 12.

4.

Alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 can support immune responses toward tumors overexpressing ganglioside D3 in mice.

Eby JM, Barse L, Henning SW, Rabelink MJ, Klarquist J, Gilbert ER, Hammer AM, Fernandez MF, Yung N, Khan S, Miller HG, Kessler ER, Garrett-Mayer E, Dilling DF, Hoeben RC, Le Poole IC.

Cancer Immunol Immunother. 2017 Jan;66(1):63-75. doi: 10.1007/s00262-016-1920-8. Epub 2016 Oct 27.

PMID:
27787577
5.

Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.

Bitzer M, Horger M, Giannini EG, Ganten TM, Wörns MA, Siveke JT, Dollinger MM, Gerken G, Scheulen ME, Wege H, Zagonel V, Cillo U, Trevisani F, Santoro A, Montesarchio V, Malek NP, Holzapfel J, Herz T, Ammendola AS, Pegoraro S, Hauns B, Mais A, Lauer UM, Henning SW, Hentsch B.

J Hepatol. 2016 Aug;65(2):280-8. doi: 10.1016/j.jhep.2016.02.043. Epub 2016 Mar 4.

PMID:
26952006
6.

Functional cloning of a gp100-reactive T-cell receptor from vitiligo patient skin.

Klarquist J, Eby JM, Henning SW, Li M, Wainwright DA, Westerhof W, Luiten RM, Nishimura MI, Le Poole IC.

Pigment Cell Melanoma Res. 2016 May;29(3):379-84. doi: 10.1111/pcmr.12458. Epub 2016 Mar 4.

PMID:
26824221
7.

Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo.

Webb KC, Tung R, Winterfield LS, Gottlieb AB, Eby JM, Henning SW, Le Poole IC.

Br J Dermatol. 2015 Sep;173(3):641-50. doi: 10.1111/bjd.14016. Epub 2015 Aug 25. Review.

8.

Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma.

Ruf B, Berchtold S, Venturelli S, Burkard M, Smirnow I, Prenzel T, Henning SW, Lauer UM.

Mol Ther Oncolytics. 2015 Oct 7;2:15019. doi: 10.1038/mto.2015.19. eCollection 2015.

9.

Targeting melanocyte and melanoma stem cells by 8-hydroxy-2-dipropylaminotetralin.

Bonchak JG, Eby JM, Willenborg KA, Chrobak D, Henning SW, Krzywiec A, Johnson SL, Le Poole IC.

Arch Biochem Biophys. 2014 Dec 1;563:71-8. doi: 10.1016/j.abb.2014.07.033. Epub 2014 Aug 14.

10.

Toward understanding the mechanism of chromophore-assisted laser inactivation--evidence for the primary photochemical steps.

Horstkotte E, Schröder T, Niewöhner J, Thiel E, Jay DG, Henning SW.

Photochem Photobiol. 2005 Mar-Apr;81(2):358-66.

PMID:
15623352
11.

Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness.

Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW, Beste G, Scroggins BT, Neckers L, Ilag LL, Jay DG.

Nat Cell Biol. 2004 Jun;6(6):507-14. Epub 2004 May 16.

PMID:
15146192
12.

Beyond the genome--SMi Conference 27-28 January 2003, London, UK.

Swinton J, Sheridan JM, Henning SW.

IDrugs. 2003 Mar;6(3):203-6.

PMID:
12838986
13.

Emerging high-throughput drug target validation technologies.

Ilag LL, Ng JH, Beste G, Henning SW.

Drug Discov Today. 2002 Sep 15;7(18 Suppl):S136-42.

PMID:
12546880
14.

The GTPase rho controls a p53-dependent survival checkpoint during thymopoiesis.

Costello PS, Cleverley SC, Galandrini R, Henning SW, Cantrell DA.

J Exp Med. 2000 Jul 3;192(1):77-85.

15.

Loss of Rho function in the thymus is accompanied by the development of thymic lymphoma.

Cleverley SC, Costello PS, Henning SW, Cantrell DA.

Oncogene. 2000 Jan 6;19(1):13-20.

16.
17.

GTPases in antigen receptor signalling.

Henning SW, Cantrell DA.

Curr Opin Immunol. 1998 Jun;10(3):322-9. Review.

PMID:
9638369
18.

Different functions of the GTPase Rho in prothymocytes and late pre-T cells.

Galandrini R, Henning SW, Cantrell DA.

Immunity. 1997 Jul;7(1):163-74.

19.

The GTPase Rho has a critical regulatory role in thymus development.

Henning SW, Galandrini R, Hall A, Cantrell DA.

EMBO J. 1997 May 1;16(9):2397-407.

20.
21.

Biological response modifiers render tumor cells susceptible to autologous effector mechanisms by influencing adhesion receptors.

Schirren CA, Völpel H, Hoffmann JC, Henning SW, Qiao L, Autschbach F, Dengler TJ, Döhner H, Meuer SC.

Leuk Lymphoma. 1993 May;10(1-2):25-33.

PMID:
7690630
22.

Supplemental Content

Loading ...
Support Center